Efficacy and safety of low-molecular-weight heparins as an adjunct to thrombolysis in acute ST-elevation myocardial infarction

Current Cardiology Reviews

Volumn 4, Issue 1, 2008, Pages 63-71

  Rubboli, Andrea ^a  

^a MAGGIORE HOSPITAL   (Italy)

Author keywords

Dalteparin; Enoxaparin; Reviparin; ST elevation acute myocardial infarction; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; REVIPARIN; STREPTOKINASE; TENECTEPLASE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; HEART REINFARCTION; HEART VENTRICLE THROMBOSIS; HOSPITAL CARE; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; STROKE; TREATMENT OUTCOME;

EID: 48249090107     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340308783565438     Document Type: Review

References (21)

1. Cheng JWM. Recognition, pathophysiology, and management of acute myocardial infarction. Am J Health Syst Pharm 2001; 58: 1709-21.
2. Ewald GA, Eisenberg PR. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation 1995; 91: 28-36.
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary and recommendation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2004; 110: 588-636.
4. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28-66.
5. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (Dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) study. J Am Coll Cardiol 1997; 30: 962-9.
6. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (Dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction - a pilot study: Biochemical Markers in Acute Coronary Syndromes (BIOMACS II). J Am Coll Cardiol 1999; 33: 627-33.
7. Wallentin L, Bergstrand L, Dellborg M, et al. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of Coronary artery patency in acute myocardial infarction - the ASSENT Plus study. Eur Heart J 2003; 24: 897-908.
8. The CREATE Trial Group Investigators. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293: 427-36.
9. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after sterptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-8.
10. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractioned heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin. Second trial of Heparin and Aspirin Reperfusion Therapy (HART-II). Circulation 2001; 104: 648-52.
11. The Assessment of the Safety and Efficacy of a New Thrombolytic regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractioned heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
12. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction. Results of the ENTIRE-Thrombolysis In Myocardial Infarction, (TIMI) 23 Trial. Circulation 2002; 105: r27-r34.
13. Baird SH, Menown IBA, McBride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractioned heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23: 627-32.
14. Simoons ML, Krzeminska-Pakula M, Alonso A, et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK Study. Eur Heart J 2002; 23: 1282-90.
15. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108: 135-42.
16. Tatu-Chitoiu G, Teodorescu C, Capraru P, et al. Accelerated streptokinase and enoxaparin in ST-segment elevation acute myocardial infarction (the ASENOX study). Pol Heart J 2004, 60: 441-6.
17. Rubboli A, Ottani F, Capecchi A, Brancaleoni R, Galvani M, Swahn E. Low-molecular-weight heparins in conjunction with thrombolysis for ST-elevation acute myocardial infarction. A critical review of the literature. Cardiology 2006; 107: 132-9.
18. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular weight mass heparins-dalteparin, enoxaparin and nadroparin - administered subcutaueously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73: 630-40.
19. Montalescot G, Collet JP, Lison L, et al. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-4.
20. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction. A meta-analysis of the randomized trials. Circulation 2005; 112: 3855-67.
21. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with thrombolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-88.